Welcome to our dedicated page for Cryo-Cell Intl SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From being the first private cord blood bank to today’s vertically integrated stem-cell storage provider, Cryo-Cell International Inc. packs every SEC filing with details that matter—specimen viability rates, PrepaCyte CB licensing revenue, and the long-term obligations tied to decades of cryogenic storage. If you have ever asked, “Where can I find Cryo-Cell International insider trading Form 4 transactions?” or “How do I read the company’s annual report 10-K simplified?”, you are in the right place.
Stock Titan layers AI-powered summaries on top of each document, so understanding Cryo-Cell International SEC documents with AI becomes effortless. Need a quick take on a Cryo-Cell International quarterly earnings report 10-Q filing? Our engine highlights cord-blood unit growth and cash-flow changes in seconds. Tracking management moves? Receive Cryo-Cell International Form 4 insider transactions real-time alerts that decode executive stock transactions before the market opens. We cover every form—10-K, 10-Q, 8-K, S-3, DEF 14A—updating the page the moment EDGAR posts.
Whether you are comparing storage fee backlogs, reviewing FDA compliance disclosures, or watching for non-routine 8-K material events explained, our platform gives practical advantages: AI-powered summaries, expert analysis, and one-click downloads of all filings. Investors rely on these tools to monitor Cryo-Cell International earnings report filing analysis, study the Cryo-Cell International proxy statement executive compensation tables, and spot patterns in Cryo-Cell International executive stock transactions Form 4. No more hunting through 200-page PDFs—discover Cryo-Cell International SEC filings explained simply.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, filed a Form 4 reporting insider changes on 09/02/2025. The filing discloses a disposition of 15,611 shares of common stock on that date at an effective price of $0.00. The explanation states the child reached majority and the reporting person no longer has beneficial ownership of those shares.
The filing also lists the reporting person’s existing beneficial holdings and derivative positions. Non-derivative holdings are shown across multiple accounts and entities (including direct holdings and interests through retirement accounts, family members, and affiliated entities). Reported stock options total significant positions including 280,000 options at $12.27 (expiring 12/22/2028) and multiple tranches of 50,000 options at various strike prices and expirations.
David I. Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company’s common stock and discloses outstanding stock options. Between 08/25/2025 and 08/27/2025 Portnoy purchased several lots through retirement accounts, including 4,500 shares at a weighted average $4.65, 5,000 shares at $4.65, 11,101 shares at $4.44, 7,860 shares at $4.42, 4,500 shares at a weighted $4.53, and 6,218 shares at $4.44. The Form 4 lists numerous indirect holdings (by 401k, IRA, spouse, LLCs and corporations) and multiple outstanding stock options with exercise prices ranging from $4.30 to $12.27 covering named share amounts up to 280,000 shares for the $12.27 option.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple purchases and a large disposal of common stock. On 08/15/2025 he acquired 2,671 shares at a weighted average price of $4.50 and 6,418 shares at a weighted average price of $4.43 through a 401(k) account; on 08/18/2025 he acquired 9,327 shares at a weighted average price of $4.37 through an IRA; and on 08/19/2025 he acquired 885 shares at $4.37 through a 401(k) account. The filing also reports a disposition of 804,742 common shares. Portnoy discloses extensive indirect holdings across personal, family and entity accounts and holds multiple outstanding stock options with various strike prices and vesting schedules.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, reported multiple transactions on Form 4. On 08/14/2025 he acquired 5,826 shares of Cryo-Cell common stock at $4.1719 per share. The filing also reports a disposition of 804,742 common shares the same date. After the reported transactions, the form lists 122,838 shares beneficially owned following the reported purchase, and numerous indirect holdings across retirement accounts, family custodial accounts, corporations, a partnership and an LLC.
The filing discloses extensive derivative holdings: stock options across multiple grants totaling specified amounts (including 280,000 options from a 12/22/2021 grant and several 50,000-option grants). Several option grants include vesting schedules and a performance vesting feature at $25.00 per share.
FAQ
What is the current stock price of Cryo-Cell Intl (CCEL)?
What is the market cap of Cryo-Cell Intl (CCEL)?
